QTTB
Q32 Bio Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 25 ▼ 3 insiders sell $75.4K at $4.51
- May 28 ▲ 2 insiders buy $30.0M at $8.00
- Jun 2 ▲ Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB…
- Jul 13 ▲ Q32 Bio reported positive 36-week topline results from Part B of the…
- Jul 15 Offering: Q32 Bio Announces Pricing of $200 Million Public Offering…
- Jul 15 ▼ Q32 Bio priced a $200 million underwritten public offering of common…
- Aug 5 ▲ Q32 Bio reported positive bempikibart 36-week topline results from t…
- Aug 25 ▼ 3 insiders sell $275.1K at $16.56
- Sep 30 ▲ 3 funds open new positions (13F)
- Sep 30 ▲ Q32 Bio presented positive Phase 2a SIGNAL-AA Part B results for bem…
- Oct 6 ▼ 3 insiders sell $45.3K at $8.32
- Oct 12 Leerink Partners initiates
Signal stack
Where each data set points today.
- InsidersBULLISH
2 insiders bought $30.0M at an average $8.00. 3 insiders sold $395.8K.
- InstitutionsBULLISH
Q3 2026: 22 added (3 new), 3 trimmed or exited. Largest new: Jpmorgan Chase & $10.1M.
- AnalystsBULLISH
13 of 14 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.304 → −$0.283 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −1.1% to 5.59M shares. 12.1 days to cover, ≈18.7% of shares.
- TrendRANGE
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | NEW | $10.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $8.3M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | $5.4M |
| MARSHALL WACE, LLP | DOUBLED | $3.1M |
| BlackRock, Inc. | DOUBLED | $2.8M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $2.0M |
| Squarepoint Ops LLC | DOUBLED | $1.6M |
| UBS Group AG | DOUBLED | $1.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
14 analystsPrice is below the lowest target. Median implies +358%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 12, 2026 | Leerink Partners INITIATE | Outperform |
| Sep 28, 2026 | Jefferies INITIATE | Buy |
| Aug 24, 2026 | Morgan Stanley INITIATE | Overweight |
| Jul 28, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Jul 13, 2026 | Oppenheimer MAINTAIN | Outperform |
| Jul 13, 2026 | Wells Fargo UPGRADE | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kalowski Lee CFO and President Oct 6, 2026 | SELL | $10.8K |
Morrison Jodie Pope CEO Oct 6, 2026 | SELL | $26.8K |
Violette Shelia M. Chief Scientific Officer Oct 6, 2026 | SELL | $7.6K |
Kalowski Lee CFO and President Aug 25, 2026 | SELL | $65.8K |
Morrison Jodie Pope CEO Aug 25, 2026 | SELL | $163.0K |
Violette Shelia M. Chief Scientific Officer Aug 25, 2026 | SELL | $46.3K |
Kalowski Lee CFO and President Jul 16, 2026 | AWARD | 53,250 sh |
Morrison Jodie Pope CEO Jul 16, 2026 | AWARD | 132,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.28 | -$0.35–-$0.21 | +6.2% | $333.3K |
| Next Q | -$0.41 | -$0.43–-$0.40 | -3.7% | $0.00 |
| Current FY | -$1.40 | -$1.46–-$1.36 | +8.0% | $333.3K |
| Next FY | -$2.16 | -$3.15–-$1.22 | -1.1% | $833.3K |
Short side
FINRA· Oct 30, 2026| Sep 30, 2026 | Volatility Pause | Resumed |
SecBot reports
22 filings · 1 press release · 5 bullish · 3 bearish · 14 neutral- NEUTRAL SC 13G/ANov 16, 2026
Biotechnology Value Fund L.P. and related entities filed an amended Schedule 13G disclosing a 9.99% aggregate beneficial ownership stake in Q32 Bio as of September 30, 2026, up from the prior 7.9% reported by Boxer Capital Management in a separate filing. The stake includes shares and pre-funded…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 16, 2026
T. Rowe Price Associates disclosed a 5.0% passive beneficial ownership stake in Q32 Bio as of September 30, 2026, consisting of 1,501,189 shares of common stock. The filing certifies passive intent and is a new 5%+ disclosure by a major asset manager, adding to recent passive stake filings by…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Sirenia Capital Management LP filed an amendment to Schedule 13G disclosing a 4.2% passive beneficial ownership stake in Q32 Bio Inc., consisting solely of 1,025,654 shares issuable upon exercise of warrants. This is a decrease from the prior 7.9% stake reported by Boxer Capital Management in a…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 6, 2026
Boxer Capital Management and related entities filed an amended Schedule 13G disclosing a 7.9%…
Monitor for any future conversion to a 13D filing, which would signal activist intent. The stake is passive for now, but the presence of multiple healthcare-focused funds (Frazier Life Sciences at…
All QTTB filing & press-release reports (23)
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 6, 2026
- SC 13G/A reportNov 6, 2026
- 8-K reportNov 4, 2026
- SC 13G reportOct 28, 2026
- SC 13G reportOct 9, 2026
- 8-K reportSep 30, 2026
- 8-K reportSep 14, 2026
- CLUSTER reportAug 27, 2026
- 8-K reportAug 5, 2026
- PRESS-RELEASE reportJul 14, 2026
- EFFECT reportJul 14, 2026
- 8-K reportJul 13, 2026
- 8-K reportJul 13, 2026
- S-3 reportJun 25, 2026
- CLUSTER reportJun 1, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 24, 2026
- 424B5 reportApr 24, 2026
- 424B5 reportMar 27, 2026
- CLUSTER reportFeb 25, 2026